Trial Profile
An open label, prospective, randomized controlled study to compare the efficacy of Ustekinumab with tumor necrosis factor inhibitor in clearing enthesitis in Psoriatic arthritis patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Dec 2017
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms ECLIPSA
- 08 Nov 2017 Results presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 07 Jul 2017 New trial record
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism